Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 25;5(2):95-101.
doi: 10.1093/skinhd/vzaf009. eCollection 2025 Apr.

Can oral minoxidil be the game changer in androgenetic alopecia? A comprehensive review and meta-analysis comparing topical and oral minoxidil for treating androgenetic alopecia

Affiliations
Review

Can oral minoxidil be the game changer in androgenetic alopecia? A comprehensive review and meta-analysis comparing topical and oral minoxidil for treating androgenetic alopecia

Faizan Fazal et al. Skin Health Dis. .

Abstract

Androgenetic alopecia (AGA) is a hair disorder seen in both sexes. Its aetiology is multifactorial. Treating AGA has always been a challenge for dermatologists. Only a few drugs such as topical minoxidil and finasteride are U.S. Food and Drug Administration-approved for treating AGA. Thus, looking for new and more effective treatment options for AGA is imperative. This review was conducted to compare the efficacy of oral with topical minoxidil in treating AGA. Only clinical trials that compared oral with topical minoxidil in treating AGA were included in this review. PubMed, Cochrane, Scopus and ClinicalTrials.gov were searched. A total of 2063 studies were retrieved from the databases. Four studies met the inclusion criteria and were included in this systematic review. Outcomes such as hair density, terminal hair density, hair count, global photographic assessment and negative hair pull were studied in this review. The results showed that there was no significant difference between oral and topical minoxidil in terms of improving the hair density of patients with AGA (overall mean difference 0.95, 95% confidence interval -24.98 to 26.87). Two studies showed that the mean difference in terminal hair density was greater in patients treated with oral minoxidil, but there was no significant difference between the two treatments in terms of improving terminal hair density. The efficacy of oral minoxidil is comparable to that of topical minoxidil in terms of improving hair density and terminal hair density in patients with AGA. Oral minoxidil can be used as an adjunct or as a second-line treatment option for AGA.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart showing study selection scheme.
Figure 2
Figure 2
Forest plot showing a comparison between oral minoxidil and topical minoxidil for hair density outcome. CI, confidence interval.
Figure 3
Figure 3
Risk of bias graph of the included studies.
Figure 4
Figure 4
Risk of bias summary of the included studies.

Similar articles

References

    1. Ntshingila S, Oputu O, Arowolo AT, Khumalo NP. Androgenetic alopecia: an update. JAAD Int 2023; 13:150–8. - PMC - PubMed
    1. Cuevas-Diaz Duran R, Martinez-Ledesma E, Garcia-Garcia M et al. The biology and genomics of human hair follicles: a focus on androgenetic alopecia. Int J Mol Sci 2024; 25:2542. - PMC - PubMed
    1. Chen S, Xie X, Zhang G et al. Comorbidities in androgenetic alopecia: a comprehensive review. Dermatol Ther (Heidelb) 2022; 12:2233–47. - PMC - PubMed
    1. Trüeb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol 2002; 37:981–90. - PubMed
    1. Aukerman EL, Jafferany M. The psychological consequences of androgenetic alopecia: a systematic review. J Cosmet Dermatol 2023; 22:89–95. - PMC - PubMed

LinkOut - more resources